Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NFIB siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
NFIB siRNA is a research-grade small interfering RNA (siRNA) reagent designed to silence the expression of the Nuclear Factor I B-type (NFIB) gene via RNA interference (RNAi). NFIB is a transcription factor involved in various developmental processes and has been implicated in the progression of several cancers, including melanoma and estrogen receptor-negative breast cancer. By targeting the NFIB transcript for degradation, this siRNA reduces NFIB protein levels, allowing researchers to study its role in cell proliferation, apoptosis, and metastasis. It is primarily used as a laboratory tool and is available from various life science reagent suppliers such as Abbexa Ltd.
- Other names
- Nuclear Factor I B-type siRNANFI-B siRNANF1-B siRNANF-1-B siRNANF 1-B siRNATGGCA-binding protein siRNA
02
Targets
TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)
Beyond the preview
Go deeper on NFIB siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NFIB siRNA.